EGFR signaling promotes prostate cancer cell invasiveness and metastasis by inducing epithelial-to-mesenchymal transition (EMT) [73,74], resistance to chemotherapy [75,76] and, ultimately, disease relapse [68,77]. This evidence concerns the gene EGFR and prostate carcinoma.